Regeneron’s Dupixent (Dupilumab) Achieves 1EP & 2EP in two P-III trial for Inadequately-Controlled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

 Regeneron’s Dupixent (Dupilumab) Achieves 1EP & 2EP in two P-III trial for Inadequately-Controlled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Shots:

  • The two P-III study involves assessing of Dupixent + SOC vs PBO (nasal spray alone) in adults with CRSwNP & Dupixent + mometasone furoate nasal spray (MFNS) vs MFNS in patients with bilateral nasal polyps
  • Two P-III (SINUS-24 & SINUS-52) study results: improvement in nasal congestion/obstruction (-1.25 &-1.34 vs -0.38 and -0.45); reduction in their nasal polyps (-1.71 & -1.89 vs 0.10 & 0.17); improved lung function and asthma control
  • Dupixent is a mAb, indicated for uncontrolled moderate-to-severe atopic dermatitis and globally jointly developed by Regeneron and Sanofi

Click here to read full press release/ article | Ref: Regeneron | Image: MultiVu

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post